EA201201676A1 - Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы - Google Patents

Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы

Info

Publication number
EA201201676A1
EA201201676A1 EA201201676A EA201201676A EA201201676A1 EA 201201676 A1 EA201201676 A1 EA 201201676A1 EA 201201676 A EA201201676 A EA 201201676A EA 201201676 A EA201201676 A EA 201201676A EA 201201676 A1 EA201201676 A1 EA 201201676A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
protein kinase
kinase inhibitors
heteroaryl compounds
compounds
Prior art date
Application number
EA201201676A
Other languages
English (en)
Russian (ru)
Inventor
Анн Мари Мадера
Даниел Пун
Аарон Смит
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201201676A1 publication Critical patent/EA201201676A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201201676A 2010-06-25 2011-06-23 Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы EA201201676A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35860310P 2010-06-25 2010-06-25
US36853410P 2010-07-28 2010-07-28
PCT/EP2011/060561 WO2011161216A1 (en) 2010-06-25 2011-06-23 Heteroaryl compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201201676A1 true EA201201676A1 (ru) 2013-06-28

Family

ID=44280749

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201676A EA201201676A1 (ru) 2010-06-25 2011-06-23 Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы

Country Status (11)

Country Link
US (1) US20130096149A1 (cg-RX-API-DMAC7.html)
EP (1) EP2585454A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013529619A (cg-RX-API-DMAC7.html)
KR (2) KR20130048293A (cg-RX-API-DMAC7.html)
CN (1) CN103080107A (cg-RX-API-DMAC7.html)
AU (1) AU2011268906A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012032884A2 (cg-RX-API-DMAC7.html)
CA (1) CA2803055A1 (cg-RX-API-DMAC7.html)
EA (1) EA201201676A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012015100A (cg-RX-API-DMAC7.html)
WO (1) WO2011161216A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113774A1 (en) 2011-02-24 2012-08-30 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
EP3515909A1 (en) 2016-09-23 2019-07-31 Cellipse Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases
DK3618875T3 (da) 2017-05-02 2023-07-10 Novartis Ag Kombinationsterapi omfattende en raf-inhibitor og trametinib
WO2020124397A1 (en) 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
CN114746419B (zh) * 2019-12-05 2023-10-24 国家医疗保健研究所 N-(3-(5-(嘧啶-4-基)噻唑-4-基)苯基)磺酰胺化合物及其用作braf抑制剂的用途
CN111320548B (zh) * 2020-04-24 2022-10-18 浦拉司科技(上海)有限责任公司 抗癌药物中间体2-氟-3-氨基苯甲酸甲酯的合成方法
US20240101516A1 (en) * 2021-01-20 2024-03-28 Basf Se Synthesis of polyfluorinated aryl and heteroaryl carboxamides
EP4499634A1 (en) 2022-03-28 2025-02-05 Nikang Therapeutics, Inc. Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
IL127210A0 (en) 1996-05-23 1999-09-22 Applied Research Systems Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US6756410B2 (en) 2000-08-30 2004-06-29 Kamal D. Mehta Induction of LDL receptor expression by extracellular-signal regulated kinase, ERK-1/2
JP2003063993A (ja) * 2001-06-11 2003-03-05 Takeda Chem Ind Ltd 医薬組成物
TWI350285B (en) 2002-03-13 2011-10-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP1799699A1 (en) 2004-10-13 2007-06-27 Wyeth Analogs of 17-hydroxywortmannin as pi3k inhibitors
JP2008531538A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 2,4−ジアミノ−ピリドピリミジン誘導体とmTOR阻害剤としてのその使用
AU2006217742A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents
HRP20120963T1 (hr) 2005-11-22 2012-12-31 Kudos Pharmaceuticals Ltd PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI
KR20080083188A (ko) 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
BRPI0715888B1 (pt) 2006-08-23 2021-11-03 Kudos Pharmaceuticals Limited Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
SG183036A1 (en) * 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EP2231625A4 (en) * 2007-12-13 2010-12-29 Glaxosmithkline Llc KINASE INHIBITORS BASED ON THIAZOLE AND OXAZOLE
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
HRP20120577T1 (hr) * 2008-07-24 2012-08-31 Nerviano Medical Sciences S.R.L. 3,4-diarilpirazoli kao inhibitori proteinskih kinaza
EP2498608A4 (en) * 2009-11-10 2013-04-24 Glaxosmithkline Llc BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS

Also Published As

Publication number Publication date
BR112012032884A2 (pt) 2016-11-08
CA2803055A1 (en) 2011-12-29
JP2013529619A (ja) 2013-07-22
CN103080107A (zh) 2013-05-01
WO2011161216A1 (en) 2011-12-29
MX2012015100A (es) 2013-05-01
AU2011268906A1 (en) 2013-01-31
KR20130048293A (ko) 2013-05-09
KR20140117684A (ko) 2014-10-07
US20130096149A1 (en) 2013-04-18
EP2585454A1 (en) 2013-05-01

Similar Documents

Publication Publication Date Title
EA201201676A1 (ru) Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
PH12017502141A1 (en) Compounds and their methods of use
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201291143A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
EA201590005A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr
EA201070595A1 (ru) Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
TR201816379T4 (tr) DNA-PK inhibitörleri.
EA201590281A1 (ru) Новые гетероарильные и гетероциклические соединения, их композиции и способы
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA201170772A1 (ru) Органические соединения
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201290642A1 (ru) Соединения и способы
EA201490846A1 (ru) Новые производные арилхинолина
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины